{"brief_title": "An Open-Label, Uncontrolled Clinical Trial of Oral 566C80 for the Treatment of Patients With Severe PCP Who Are Intolerant and/or Unresponsive to Therapy With Trimethoprim/Sulfamethoxazole and Parenteral Pentamidine", "brief_summary": "To facilitate provision of atovaquone (566C80) to patients who have severe Pneumocystis carinii pneumonia (PCP) and are intolerant and/or unresponsive to trimethoprim / sulfamethoxazole ( TMX / SMX ); to monitor serious adverse events attributable to 566C80.", "condition": ["Pneumonia, Pneumocystis Carinii", "HIV Infections"], "intervention_type": ["Drug"], "intervention_name": ["Atovaquone"], "criteria": "Inclusion Criteria Patients must have the following: - Clinical diagnosis of acute severe Pneumocystis carinii pneumonia (PCP). - Dose-limiting intolerance to TMP / SMX and parenteral pentamidine. - Willingness and ability to give informed consent. Exclusion Criteria Co-existing Condition: Excluded: - Patients with a history of intolerance to 566C80. Patients with the following prior conditions are excluded: History of serious dose-limiting adverse experience during previous 566C80 therapy, thought to be attributable to the drug. Required: - Trimethoprim / sulfamethoxazole (TMP/SMX); pentamidine.", "gender": "All", "minimum_age": "N/A", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "atovaquone", "mesh_term": ["HIV Infections", "Pneumonia", "Pneumonia, Pneumocystis", "Sulfamethoxazole", "Trimethoprim", "Pentamidine", "Atovaquone", "Trimethoprim, Sulfamethoxazole Drug Combination"], "id": "NCT00001990"}